TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $93 | -41.5% | 10,383 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $159 | -15.4% | 10,383 | +23.9% | 0.00% | -50.0% |
| Q1 2023 | $188 | -6.9% | 8,379 | -12.8% | 0.00% | 0.0% |
| Q4 2022 | $202 | -99.9% | 9,611 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $237,000 | +3.5% | 9,611 | +1.5% | 0.00% | 0.0% |
| Q2 2022 | $229,000 | +21.8% | 9,470 | +29.9% | 0.00% | +100.0% |
| Q1 2022 | $188,000 | -61.2% | 7,293 | -53.2% | 0.00% | -50.0% |
| Q4 2021 | $484,000 | +132.7% | 15,594 | +103.9% | 0.00% | -75.0% |
| Q4 2020 | $208,000 | – | 7,649 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |